Can metformin and empagliflozin be added to insulin glargine therapy, and which insulin glargine brand is best in the Philippines?

Yes, metformin and empagliflozin can absolutely be added to insulin glargine therapy

The combination of metformin + empagliflozin + insulin glargine is not only safe but strongly recommended by current 2025 ADA guidelines, particularly if the patient has cardiovascular disease, heart failure, or chronic kidney disease. 1

Evidence Supporting Triple Combination Therapy

Guideline-Based Recommendations

The 2025 ADA Standards of Care explicitly support this combination 1:

• SGLT2 inhibitors (empagliflozin) and metformin should be used WITH insulin when patients have established cardiovascular disease, heart failure, or CKD—independent of A1C levels
• These medications provide benefits beyond glucose control: cardiovascular protection, kidney protection, and reduced heart failure hospitalizations
• Patients already on insulin who have these comorbidities should have SGLT2 inhibitors and/or GLP-1 RAs added to reduce cardiovascular and kidney risks

Clinical Trial Evidence

The FDA label for empagliflozin 2 documents a dedicated trial of empagliflozin added to insulin glargine (with or without metformin):

• 494 patients with type 2 diabetes on basal insulin participated in a 78-week study
• Empagliflozin 10 mg or 25 mg added to insulin glargine produced:
  • HbA1c reduction of -0.6% to -0.7% at 18 weeks (vs 0% with placebo)
  • Sustained HbA1c reduction of -0.5% to -0.7% at 78 weeks (vs +0.1% with placebo)
  • Weight loss of 2.4% (vs weight gain of 0.7% with placebo)
  • No increase in hypoglycemia risk (35-36% in all groups)
  • Reduced insulin dose requirements over time

A 2015 research study 3 confirmed these findings over 78 weeks, showing empagliflozin added to basal insulin improved glycemic control and reduced weight with similar hypoglycemia risk to placebo.

Metformin Considerations

Metformin remains a preferred agent and can be safely combined with insulin glargine 1:

• Key safety consideration: Check eGFR before adding metformin
  • Do NOT start if eGFR <45 mL/min/1.73 m²
  • Reduce dose if eGFR <45 mL/min/1.73 m²
  • Stop if eGFR <30 mL/min/1.73 m²

A 2011 analysis 4 showed that adding insulin glargine to metformin monotherapy resulted in better outcomes than adding it to sulfonylurea-containing regimens, with less hypoglycemia and weight gain.

Triple Combination Data

A 2024 study 5 specifically evaluated initial triple therapy with metformin + sitagliptin + empagliflozin in drug-naïve patients over 24 months:

• 72.5% achieved HbA1c <7% at 12 months, 61.7% at 24 months
• No serious adverse events including ketoacidosis
• Improved metabolic parameters and reduced albuminuria

While this wasn't with insulin glargine, it demonstrates the safety and efficacy of combining metformin with empagliflozin.

Practical Implementation Algorithm

Step 1: Assess kidney function (eGFR)

• If eGFR ≥45: Can use both metformin and empagliflozin
• If eGFR 20-44: Can use empagliflozin; reduce or avoid metformin
• If eGFR <20: Avoid both

Step 2: Start empagliflozin 10 mg daily (can increase to 25 mg if needed)

Step 3: Continue or add metformin (if eGFR permits) at standard doses

Step 4: Monitor for:

• Genital infections (8% with empagliflozin 10 mg, 5% with 25 mg) 3
• Urinary tract infections (15% with empagliflozin 10 mg, 12% with 25 mg) 3
• Volume depletion (especially in elderly or those on diuretics)
• No need to increase hypoglycemia monitoring beyond standard insulin monitoring

Step 5: Insulin dose adjustment

• Insulin requirements typically decrease over time with empagliflozin 2, 3
• Consider reducing basal insulin by 10-20% when starting empagliflozin if baseline glucose is well-controlled to avoid hypoglycemia

Common Pitfalls to Avoid

1. Don't wait for A1C to be uncontrolled before adding empagliflozin if the patient has cardiovascular disease, heart failure, or CKD—the benefits are independent of glycemic control 1

2. Don't fear hypoglycemia with this combination—the risk is similar to insulin alone 2, 3

3. Don't forget to check kidney function before starting metformin or empagliflozin

4. Don't use empagliflozin in type 1 diabetes or diabetic ketoacidosis

---

Best Insulin Glargine Brand in the Philippines

Lantus (Sanofi) remains the reference standard insulin glargine 100 U/mL (Gla-100) globally, with the most extensive clinical trial data over two decades 6. However, Toujeo (insulin glargine 300 U/mL, Gla-300) offers advantages over Gla-100 including lower nocturnal hypoglycemia risk, >24-hour duration of action, and more stable glucose-lowering profile 6.

Available Options in the Philippines

The main insulin glargine formulations available are:

1. Lantus (Gla-100) - Original reference product
2. Toujeo (Gla-300) - More concentrated formulation with improved profile
3. Biosimilar glargine products (various manufacturers) - Cost-effective alternatives

Clinical Considerations

A 2024 comprehensive review 6 comparing insulin glargine formulations in clinical trials found:

• Gla-300 (Toujeo) vs Gla-100 (Lantus):

  • Comparable overall hypoglycemia risk
  • Lower nocturnal hypoglycemia with Gla-300
  • Prolonged >24-hour duration with Gla-300
  • More stable glucose-lowering profile with Gla-300
  • Greater flexibility in dosing timing with Gla-300
  • Improved treatment satisfaction with Gla-300

• Both formulations are comparable to other basal insulins (detemir, degludec) for glucose-lowering in type 2 diabetes

Practical Recommendation

If cost is not a barrier, Toujeo (Gla-300) is the superior choice due to lower nocturnal hypoglycemia and greater dosing flexibility 6. If cost is a concern, Lantus or quality biosimilar glargine products are acceptable alternatives with extensive safety and efficacy data.

The choice should factor in:

• Patient's hypoglycemia risk (higher risk → prefer Toujeo)
• Dosing schedule flexibility needs (variable schedule → prefer Toujeo)
• Cost and insurance coverage (limited budget → biosimilar acceptable)
• Local availability and supply chain reliability